ClinicalTrials.gg
RecruitingNCT05534646Updated Oct 5, 2026

Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

A Phase 2 interventional study of AR Blockade and Carotuximab in Castration-resistant Prostate Cancer, sponsored by Edwin Posadas, MD. Recruiting at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Edwin Posadas, MD · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.
Updated Oct 5, 2026Interventions changedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
832nd of 3,023
116 · median 48
Started
2023
with 157 others
Phase 2
1,063 of 3,596
145 open now
Primary completion
2028-01
later than 611 of 971 live
Registered
2,922nd of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 832nd largest by planned enrollment of the 3,023 interventional ones that give a count, is one of 158 that started in 2023, is one of 1,063 in phase 2, reaches primary completion later than 611 of the 971 other live ones, and was the 2,922nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

03

Conditions studied

  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • Prostate cancer
  • Castration-resistant
  • CRPC
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of castration-resistant prostate cancer with rising PSA on a contemporary ARSI (e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.

    • PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
    • Patient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
    • Patient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
    • Patients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
  • Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.
  • Have (ECOG) performance status (PS) of 0-1
  • Resolution of adverse events results as described below:

    • If the subject's patient's most recent is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
    • If the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to grade 2)
  • Adequate organ function
  • All patients must agree to use an adequate method of , in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)
  • Written obtained from subject and ability for subject to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
  • Other prior requiring active anticancer therapy
  • Prior exposure to carotuximab or any CD105 targeted antibody
  • Any major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
  • Uncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
  • Active bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
  • Use of thrombolytics within 10 days prior to the first day of carotuximab
  • Known to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
  • A known diagnosis of Osler-Weber-Rendu syndrome
  • Ascites or pericardial or pleural effusion requiring external drainage procedures
  • History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or . Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
  • Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, Class II or worse congestive heart failure, cerebrovascular accident, , arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
  • Deep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Active comparator
    Enzalutamide Naive - Monotherapy

    After progression, subjects will crossover to combination therapy

    Drug: AR Blockade

  • Experimental
    Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab)

    Androgen Receptor is Apalutamide 240mg for Lead-In group \& Enzalutamide 160mg for all other groups

    Drug: AR Blockade · Drug: Carotuximab

  • Experimental
    Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)

    Androgen Receptor is Apalutamide 240mg for Lead-In group \& Enzalutamide 160mg for all other groups

    Drug: AR Blockade · Drug: Carotuximab

Interventions

  • Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle

    Also known as: Apalutamide, Enzalutamide

  • Carotuximab administered intravenously at the following doses: Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.

06

What researchers measure

Primary outcomes

  1. Progression free survival (rPFS) between patients receiving AR blockade and AR blockade + carotuximab

    From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

    Time frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

Secondary outcomes

  1. Incidence of Adverse events (grade 3 or higher) related to carotuximab and AR blockade

    Grade 3 or above treatment related adverse events as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From start of study treatment through 4 weeks on treatment

  2. Overall radiographic response rate (ORR) of the combination of AR blockade + carotuximab

    Participants of the combination of AR blockade + carotuximab, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

    Time frame: From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

  3. Proportion of patients resistant to AR blockade benefit from the addition of carotuximab

    Participants of the monotherapy group that crossover to combination therapy at progression, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3

    Time frame: From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

  4. Overall radiographic response rate (ORR) in the overall population

    Determined by confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3

    Time frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

  5. To determine the radiographic progression free survival (rPFS) in the overall population

    From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause.

    Time frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

  6. To determine the biochemical PFS (by PCWG3) in the overall population

    From the start of study treatment until documented progression, per Prostate Cancer Working Group 3, or death due to any cause.

    Time frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jan 2028, 49 months after the start.

Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's planned 49 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 9, 2022
StartActual
Dec 27, 2023
Primary completionEst.
Jan 2028was Jan 2027
CompletionEst.
Jan 2028was Jan 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Jan 2028
Sep 30, 2026
Study completion
Jan 2027→Jan 2028
Sep 30, 2026
Enrollment
100→116
Sep 30, 2026
Eligibility
3 inclusion criteria edited, 9 added; 1 exclusion criterion edited, 8 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedHistory of castration-resistant prostate cancer with rising PSA (prostate-specific antigen) on a contemporary ARSI (Androgen receptor (AR) signaling inhibitor:e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.
  • AddedPSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
  • AddedPatient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
  • EditedPatient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
  • AddedPatients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
  • AddedHave Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
  • AddedResolution of adverse events results as described below:
  • AddedIf the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
  • AddedIf the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
  • AddedAdequate organ function
  • EditedAll patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)
  • AddedWritten informed consent obtained from subject and ability for subject to comply with the requirements of the study
Exclusion criteria
  • RemovedPrior use of apalutamide
  • AddedAny major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
  • AddedUncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
  • EditedActive bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
  • AddedUse of thrombolytics within 10 days prior to the first day of carotuximab
  • AddedKnown hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
  • AddedAscites or pericardial or pleural effusion requiring external drainage procedures
  • AddedHistory of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
  • AddedAcute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
  • AddedDeep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.
Sep 30, 2026
Interventions
Changed Apalutamide→AR Blockade. Arm changed Apalutamide monotherapy→Enzalutamide Naive - Monotherapy; Combination therapy (Apalutamide + Carotuximab)→Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab); Enzalutamide Exposed - Combination therapy (AR Blockade + Carotuximab)→Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab). Arms added: Enzalutamide Exposed - Combination therapy (AR Blockade + Carotuximab)
across 2 updates, Sep 30, 2026 – Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProgression free survival (rPFS) between patients receiving apalutamideAR blockade and apalutamideAR blockade + carotuximabTime frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Sep 30, 2026
Secondary outcomes
3 edited
What changed in the outcomes
  • EditedIncidence of Adverse events (grade 3 or higher) related to carotuximab and apalutamideAR blockadeTime frame: From start of study treatment through 4 weeks on treatment
  • EditedOverall radiographic response rate (ORR) of the combination of apalutamideAR blockade + carotuximabTime frame: From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
  • EditedProportion of patients resistant to apalutamideAR blockade benefit from the addition of carotuximabTime frame: From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
Sep 30, 2026
Contact
Study contact changed: •••2133→•••5842; c•••@cshs.org→G•••@cshs.org; added e•••@csmc.edu. See the current contact
Sep 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact •••2133→•••5842Contact c•••@cshs.org→G•••@cshs.orgContact added e•••@csmc.edu
Sep 30, 2026
Title
Study of ApalutamideAR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancerCanc
Sep 30, 2026
Sponsor
Collaborators added: Kairos Pharma; collaborators removed: Enviro Therapeutics, Inc.
Sep 30, 2026
Show all 2 updates
  1. Oct 5, 2026
    Interventions Arm changed Enzalutamide Naive - Combination therapy (AR Blockade + Carotuximab)→Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab); Enzalutamide Exposed - Combination therapy (AR Blockade + Carotuximab)→Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)
  2. Sep 30, 2026
    Primary completion Jan 2027→Jan 2028
    Study completion Jan 2027→Jan 2028
    Enrollment 100→116
    Eligibility 3 inclusion criteria edited, 9 added; 1 exclusion criterion edited, 8 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedHistory of castration-resistant prostate cancer with rising PSA (prostate-specific antigen) on a contemporary ARSI (Androgen receptor (AR) signaling inhibitor:e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.
    • AddedPSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
    • AddedPatient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
    • EditedPatient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
    • AddedPatients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
    • AddedHave Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
    • AddedResolution of adverse events results as described below:
    • AddedIf the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
    • AddedIf the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
    • AddedAdequate organ function
    • EditedAll patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)
    • AddedWritten informed consent obtained from subject and ability for subject to comply with the requirements of the study
    Exclusion criteria
    • RemovedPrior use of apalutamide
    • AddedAny major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
    • AddedUncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
    • EditedActive bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
    • AddedUse of thrombolytics within 10 days prior to the first day of carotuximab
    • AddedKnown hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
    • AddedAscites or pericardial or pleural effusion requiring external drainage procedures
    • AddedHistory of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
    • AddedAcute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
    • AddedDeep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProgression free survival (rPFS) between patients receiving apalutamideAR blockade and apalutamideAR blockade + carotuximabTime frame: From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
    Secondary outcomes 3 edited
    What changed in the outcomes
    • EditedIncidence of Adverse events (grade 3 or higher) related to carotuximab and apalutamideAR blockadeTime frame: From start of study treatment through 4 weeks on treatment
    • EditedOverall radiographic response rate (ORR) of the combination of apalutamideAR blockade + carotuximabTime frame: From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
    • EditedProportion of patients resistant to apalutamideAR blockade benefit from the addition of carotuximabTime frame: From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
    Interventions Changed Apalutamide→AR Blockade. Arm changed Apalutamide monotherapy→Enzalutamide Naive - Monotherapy; Combination therapy (Apalutamide + Carotuximab)→Enzalutamide Naive - Combination therapy (AR Blockade + Carotuximab). Arms added: Enzalutamide Exposed - Combination therapy (AR Blockade + Carotuximab)
    Sponsor Collaborators added: Kairos Pharma; collaborators removed: Enviro Therapeutics, Inc.
    Contact Study contact changed: •••2133→•••5842; c•••@cshs.org→G•••@cshs.org; added e•••@csmc.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact •••2133→•••5842Contact c•••@cshs.org→G•••@cshs.orgContact added e•••@csmc.edu
    Title Study of ApalutamideAR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancerCanc
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05534646
Lead sponsor
Edwin Posadas, MD
Collaborators
Kairos Pharma
Responsible party
Edwin Posadas, MD (Co-Director, Experimental Therapeutics Program, Cedars-Sinai Medical Center) — Sponsor-investigator
First posted
Sep 9, 2022
Start date
Dec 27, 2023
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Clinical Trial Recruitment Navigator
Contact
GroupCancerTrialInformation@cshs.org
310-423-5842
Edwin Posadas, MD FACP
Contact
edwin.posadas@csmc.edu
Edwin Posadas, MD FACP
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carotuximab

Start the discussion